Leflunomide-13C6

• Description :

  Leflunomide-13C6 (HWA486-13C6) is 13C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.

• Product Name Alternative :

  HWA486-13C6; RS-34821-13C6; SU101-13C6

• UNSPSC :

  12352005

• Target :

  Bacterial; Dihydroorotate Dehydrogenase; Endogenous Metabolite; Isotope-Labeled Compounds

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease; Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Smiles :

  O=C(C1=C(C)ON=C1)N[13C]2=[13C][13C]=[13C](C(F)(F)F)[13C]=[13C]2

• Molecular Formula :

  C6 13C6H5F3N2O2

• Molecular Weight :

  272.13

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Fox RI, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999 Dec;93 (3) :198-208.|[3]Xu X, et al. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem. 1995 May 26;270 (21) :12398-403.|[4]Davis JP, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry. 1996 Jan 30;35 (4) :1270-3.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported